Alessia Petrocchi
IRBM Science Park(IT)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, HIV/AIDS drug development and treatment, Protein Tyrosine Phosphatases, Chromatin Remodeling and Cancer, Cancer Mechanisms and Therapy
Most-Cited Works
- → An inhibitor of oxidative phosphorylation exploits cancer vulnerability(2018)924 cited
- → Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection(2008)627 cited
- → The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies(2015)268 cited
- → Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor(2012)201 cited
- → Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor(2015)155 cited
- → Discovery of α,γ-Diketo Acids as Potent Selective and Reversible Inhibitors of Hepatitis C Virus NS5b RNA-Dependent RNA Polymerase(2003)122 cited
- → 4,5-Dihydroxypyrimidine Carboxamides and N-Alkyl-5-hydroxypyrimidinone Carboxamides Are Potent, Selective HIV Integrase Inhibitors with Good Pharmacokinetic Profiles in Preclinical Species(2006)99 cited
- → HCV NS5b RNA-Dependent RNA Polymerase Inhibitors: From α,γ-Diketoacids to 4,5-Dihydroxypyrimidine- or 3-Methyl-5- hydroxypyrimidinonecarboxylic Acids. Design and Synthesis(2004)91 cited
- → Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer(2015)82 cited
- → Dihydroxypyrimidine-4-carboxamides as Novel Potent and Selective HIV Integrase Inhibitors(2007)76 cited